Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327631 | 0.87 | CNR2 (0.53) | CNR2CNR1PSMB8PSMB5HPGD | |
| SCHEMBL2327625 | 0.87 | CNR2 (0.53) | CNR2CNR1PSMB8PSMB5HPGD | |
| SCHEMBL2330596 | 0.83 | CTSG (0.45) | KMT2AITGB3ITGA2B | |
| SCHEMBL2328570 | 0.81 | CNR2 (0.54) | CNR2CNR1PSMB8PSMB5KEAP1 | |
| SCHEMBL24130594 | 0.79 | HPGD (0.65) | CNR2CNR1PSMB8PSMB5KEAP1 | |
| SCHEMBL10658899 | 0.79 | CA2 (0.51) | HPGDMEN1KMT2A | |
| SCHEMBL24831957 | 0.79 | ALDH1A1 (0.64) | CNR2CNR1PSMB8PSMB5KEAP1 | |
| SCHEMBL10658891 | 0.79 | CA2 (0.51) | HPGDMEN1KMT2A | |
| SCHEMBL24130591 | 0.79 | HPGD (0.65) | CNR2CNR1PSMB8PSMB5KEAP1 | |
| SCHEMBL1458952 | 0.78 | PSMB8 (0.67) | CNR2CNR1PSMB8PSMB5KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | CNR2 1779/4885CNR1 1303/4885PSMB8 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.